Clinical and Translational Allergy (Sep 2024)

Concurrent validity, cut‐offs and ability to change of patient‐reported outcome measures for rhinitis and asthma in MASK‐air®

  • Jean Bousquet,
  • Bernardo Sousa‐Pinto,
  • Josep M. Anto,
  • Anna Bedbrook,
  • Wienczyslawa Czarlewski,
  • Ignacio J. Ansotegui,
  • Karl‐C. Bergmann,
  • Fulvio Braido,
  • Luisa Brussino,
  • Lorenzo Cecchi,
  • Claudia Chaves Loureiro,
  • Alvaro A. Cruz,
  • Philippe Devillier,
  • Alessandro Fiocchi,
  • Bilun Gemicioglu,
  • Tari Haahtela,
  • Juan Carlos Ivancevich,
  • Ludger Klimek,
  • Marek Kulus,
  • Piotr Kuna,
  • Maciej Kupczyk,
  • Violeta Kvedariene,
  • Desiree E. Larenas‐Linnemann,
  • Gilles Louis,
  • Renaud Louis,
  • Michael Makris,
  • Mario Morais‐Almeida,
  • Marek Niedoszytko,
  • Ken Ohta,
  • Markus Ollert,
  • Nikolaos Papadopoulos,
  • Vincenzo Patella,
  • Benoit Pétré,
  • Oliver Pfaar,
  • Francesca Puggioni,
  • Santiago Quirce,
  • Frederico S. Regateiro,
  • Nicolas Roche,
  • Philip W. Rouadi,
  • Boleslaw Samolinski,
  • Joaquin Sastre,
  • Florence Schleich,
  • Nicola Scichilone,
  • Luis Taborda‐Barata,
  • Sanna Toppila‐Salmi,
  • Arunas Valiulis,
  • Ilgim Vardaloglu Koyuncu,
  • Maria Teresa Ventura,
  • Arzu Yorgancioglu,
  • Joao A. Fonseca,
  • Torsten Zuberbier

DOI
https://doi.org/10.1002/clt2.12390
Journal volume & issue
Vol. 14, no. 9
pp. n/a – n/a

Abstract

Read online

Abstract Patient‐reported outcome measures (PROMs) are used to assess a patient's health status at a particular point in time. They are essential in the development of person‐centred care. This paper reviews studies performed on PROMs for assessing AR and asthma control, in particular VAS scales that are included in the app MASK‐air® (Mobile Airways Sentinel networK) for asthma and rhinitis. VASs were initially developed on paper and pencil and tested for their criterion validity, cut‐offs and responsiveness. Then, a multicentric, multinational, double‐blind, placebo‐controlled, randomised control trial (DB‐PC‐RCT) using an electronic VAS form was carried out. Finally, with the development of MASK‐air® in 2015, previously validated VAS questions were adapted to the digital format and further methodologic evaluations were performed. VAS for asthma, rhinitis, conjunctivitis, work and EQ‐5D are included in the app. Additionally, two control‐medication scores for allergic symptoms of asthma (e‐DASTHMA) were validated for their criterion validity, cut‐offs and responsiveness.

Keywords